DSM to expand gut health portfolio with BioCare Copenhagen deal

By Nathan Gray

- Last updated on GMT

DSM to expand gut health portfolio with BioCare Copenhagen deal

Related tags Gut health Probiotic Gut flora Nutrition

Global nutritional ingredients player DSM has acquired BioCare Copenhagen A/S in a deal that will see it expand its probiotic and gut health portfolio.

Netherlands-based DSM already has a strong position in gut health with its Culturelle probiotic product range, in addition to Oatwell and Tolerase brands, making up existing positioning. However, the company said it sees further growth potential in gut health ingredients beyond the established indications for digestive health and immune health.

BioCare Copenhagen is a privately-held company founded in 2012, focused on probiotics and specialised in microbial actives with proven health benefits, targeting gastrointestinal disorders, metabolic disorders, infections, and immunity.

“Fields increasingly recognized as being impacted by the gut microbiome include the gut-brain axis, metabolic health and heart health,”​ said DSM in a press release – which added that the firm’s ambition in addressing the gut microbiome and its portfolio of nutritional ingredients “are very synergetic with BioCare Copenhagen’s approach and products, and the combination is well-catered to address the existing and emerging gut health areas.”

DSM noted that BioCare offers high-quality white label probiotic supplements and complete product concepts with strong consumer appeal. It added that the Danish company already has multi-market distribution agreements with a number of leading dietary supplements and pharmaceutical companies and has launched products in over 40 countries worldwide.

With a market growth estimated at 7% per year, DSM said gut health ingredients and probiotics are ‘an attractive market segment in nutritional ingredients’.

No financial details of the deal have been disclosed currently, DSM confirmed.

Related products

show more

Redefine resilience with IMMUSE

Redefine resilience with IMMUSE

Content provided by Kyowa Hakko (US) | 02-May-2024 | White Paper

IMMUSETM is a universal postbiotic — the first of its kind to activate pDC cells for year-round immune support.

NAD+ Booster NMNH Proved for Safety and Efficacy

NAD+ Booster NMNH Proved for Safety and Efficacy

Content provided by Effepharm Ltd | 02-May-2024 | Product Brochure

NMNH, short for Reduced Beta-Nicotinamide Mononucleotide, refers to the reduced form of NMN. Preclinical studies show that NMNH demonstrates a remarkable...

Related suppliers

Follow us

Products

View more

Webinars